Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 7/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767411 | 0.84 | PTGDR2 (0.67) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL5029669 | 0.83 | PTGDR2 (0.45) | PTGDR2AKR1B1CYP2C9SLC6A4TP53 | |
| SCHEMBL27695720 | 0.80 | PTGDR2 (0.54) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL1405972 | 0.77 | PTGDR2 (0.79) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL11891652 | 0.76 | PTGDR2 (0.61) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL1056786 | 0.75 | PTGDR2 (0.46) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL6511408 | 0.73 | PTGDR2 (0.43) | PTGDR2AKR1B1CYP2C9SLC6A4TP53 | |
| SCHEMBL28757670 | 0.66 | ALDH1A1 (0.36) | PTGDR2AKR1B1CYP2C9SLC6A4TP53 | |
| SCHEMBL15015951 | 0.65 | LIPE (0.36) | PTGDR2AKR1B1CYP2C9TP53 | |
| SCHEMBL15015952 | 0.65 | LIPE (0.36) | PTGDR2AKR1B1CYP2C9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051586-A1 | Novel Process for the Preparation of Substituted Indoles | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| EP-1844012-A2 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLES | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006075139-A2 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLES | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051586-A1 | Novel Process for the Preparation of Substituted Indoles | IDO1, IDO2, TPH1 | PTGDR2 390/4885AKR1B1 341/4885CYP2C9 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.